AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating.
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: acimmune.com/en/investors
| Impact snapshot | Event time: | ACIU | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ACIU alerts
ACIU alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual ConferenceGlobeNewswire
- AC Immune to Highlight Promising Alzheimer’s Vaccine at the SVB Leerink 10th Annual Global Healthcare ConferenceGlobeNewswire
- AC Immune Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s DiseaseGlobeNewswire
- AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome PathwayGlobeNewswire
- AC Immune SA (<a href="https://www.marketbeat.com/stocks/NASDAQ/ACIU/price-target/">NASDAQ: ACIU</a>) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.MarketBeat
- More
ACIU
SEC Filings
- 2/26/21 - Form 6-K
- 2/12/21 - Form SC
- 2/12/21 - Form SC
- ACIU's page on the SEC website
- More